Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company,
ID: 2462765 • Letter: A
Question
Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2014.
FITZGERALD PHARMACEUTICAL INDUSTRIES
SELECTED BALANCE SHEET
INFORMATION
JUNE 30, 2014
Long-term debt
Notes payable, 10%
$1,159,000
7% convertible bonds payable
5,191,000
10% bonds payable
6,077,000
Total long-term debt
$12,427,000
Shareholders’ equity
Preferred stock, 6% cumulative, $57 par value, 108,900 shares authorized, 27,225 shares issued and outstanding
$1,551,825
Common stock, $1 par, 10,080,000 shares authorized, 1,008,000 shares issued and outstanding
1,008,000
Additional paid-in capital
4,003,700
Retained earnings
6,009,000
Total shareholders’ equity
$12,572,525
The following transactions have also occurred at Fitzgerald.
1.
Options were granted on July 1, 2013, to purchase 206,900 shares at $15 per share. Although no options were exercised during fiscal year 2014, the average price per common share during fiscal year 2014 was $20 per share.
2.
Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 57 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2013.
3.
The preferred stock was issued in 2013.
4.
There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2014.
5.
The 1,008,000 shares of common stock were outstanding for the entire 2014 fiscal year.
6.
Net income for fiscal year 2014 was $1,524,000, and the average income tax rate is 45%.
For the fiscal year ended June 30, 2014, calculate the following for Fitzgerald Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)
(a) Basic earnings per share.
Basic earnings per share
$
(b) Diluted earnings per share.
Diluted earnings per share
$
FITZGERALD PHARMACEUTICAL INDUSTRIES
SELECTED BALANCE SHEET
INFORMATION
JUNE 30, 2014
Long-term debt
Notes payable, 10%
$1,159,000
7% convertible bonds payable
5,191,000
10% bonds payable
6,077,000
Total long-term debt
$12,427,000
Shareholders’ equity
Preferred stock, 6% cumulative, $57 par value, 108,900 shares authorized, 27,225 shares issued and outstanding
$1,551,825
Common stock, $1 par, 10,080,000 shares authorized, 1,008,000 shares issued and outstanding
1,008,000
Additional paid-in capital
4,003,700
Retained earnings
6,009,000
Total shareholders’ equity
$12,572,525
Explanation / Answer
$
$
Net income 2014
15,24,000
Less:
Int on 10% On Notes
1,15,900
Less:
Int on 7% Convertible Bonds
3,63,370
Less:
In on 10% Bond
6,07,700
Total interest Payable
10,86,970.00
10,86,970.00
Profit after int. but before taxes
4,37,030.00
Less:
Tax@45%
1,96,663.50
Net earning for shareholder
2,40,366.50
6% Pref.Dividend
93,109.50
27225x5x7*6%
Net earning for Common Stock
1,47,257
No of Stock Outstanding
10,80,000
Basic earning per share
0.14
Diluted share
5191000/100
51910
Diluted earning
240366.5-(93109.50+6% of51910)
Diluted earning share
1,44,142.40
No of stock outstanding
108000
Diluted earning per share
144142.40/1080000
=
0.13
$
$
Net income 2014
15,24,000
Less:
Int on 10% On Notes
1,15,900
Less:
Int on 7% Convertible Bonds
3,63,370
Less:
In on 10% Bond
6,07,700
Total interest Payable
10,86,970.00
10,86,970.00
Profit after int. but before taxes
4,37,030.00
Less:
Tax@45%
1,96,663.50
Net earning for shareholder
2,40,366.50
6% Pref.Dividend
93,109.50
27225x5x7*6%
Net earning for Common Stock
1,47,257
No of Stock Outstanding
10,80,000
Basic earning per share
0.14
Diluted share
5191000/100
51910
Diluted earning
240366.5-(93109.50+6% of51910)
Diluted earning share
1,44,142.40
No of stock outstanding
108000
Diluted earning per share
144142.40/1080000
=
0.13
Related Questions
drjack9650@gmail.com
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.